Understanding how genetics affect responses to a diabetes medication
Pharmacogenetics of the Response to a GLP1R Agonist
This study is looking at how your genes might affect how well a diabetes medication called semaglutide works for you, and it's specifically for members of the Old Order Amish community to help find out who will get the most benefit from this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11009931 on NIH RePORTER |
What this research studies
This research investigates how genetic differences influence the effectiveness of GLP1R agonists, a class of medications used to treat diabetes. By focusing on the Old Order Amish population, the study aims to identify specific genetic variants that predict how well individuals respond to these drugs. Participants will undergo glucose tolerance tests before and after treatment with semaglutide, allowing researchers to measure changes in their glucose levels and other health indicators. The goal is to develop a method to identify patients who will benefit most from this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are overweight or obese individuals from the Old Order Amish community who are otherwise healthy and have adult-onset diabetes.
Not a fit: Patients who do not belong to the Old Order Amish population or those with other significant health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized diabetes treatments that improve patient outcomes and reduce the risk of complications.
How similar studies have performed: Similar research has shown promise in identifying genetic factors that influence drug responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Beitelshees, Amber L — University of Maryland Baltimore
- Study coordinator: Beitelshees, Amber L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.